Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv

Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv Publisher Pubmed

Taki E¹ ; Soleimani F² ; Asadi A^{3, 4} ; Ghahramanpour H⁵ ; Namvar A⁶ ; Heidary M^{7, 8}

Show Affiliations

1. Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Chemistry, Medicinal Chemistry Research Laboratory, Shiraz University of Technology, Shiraz, Iran
3. Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4. Microbial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran
5. Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
6. Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran
7. Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran
8. Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

Source: Expert Review of Anti-Infective Therapy Published:2022

Abstract

Introduction: The development of long-acting (LA) drugs has changed the management of common medical conditions for human replication immunodeficiency virus (HIV). Cabenuva (cabotegravir/Rilpivirine) is the first LA antiretroviral injectable drug composed of nano-formulation of cabotegravir (CAB) and rilpivirine (RPV). Areas covered: In this review article, we aim to have a brief overview of results of major clinical trials that administrated Cabotegravir/Rilpivirine for patients considering the efficacy and safety profiles. Moreover, we discuss about CAB and RPV chemical structure, mechanism of action, ‎activity against drug-sensitive and -resistant HIV, and pharmacodynamics/pharmacokinetics properties. Expert opinion: Based on the results of the ATLAS and FLAIR trials, Cabotegravir/Rilpivirine regimen once-monthly has shown equal effectivity to oral combination antiretroviral therapy (cART) in maintaining HIV-1 suppression in patients. Furthermore, ATLAS-2 M study revealed the non-inferiority of Cabotegravir/Rilpivirine regimen every 8 weeks compared to every 4 weeks. The injectable LA ART reduces the number of treatment intake as well as increases adherence, especially in patients with HIV-related stigma. Administration of extended-release agents probably minimize the risk of treatment-related toxicity and resistance related to sub-optimal adherence to oral ART, so Cabotegravir/Rilpivirine can be suggested as a suitable alternative for HIV infection control in current era. © 2022 Informa UK Limited, trading as Taylor & Francis Group.

2. Exploring the Application of Immunotherapy Against Hiv Infection in the Setting of Malignancy: A Detailed Review Article, International Immunopharmacology (2022)

Experts (# of related papers)

Nima Rezaei (1)

Seyed Ahmad Seyed Alinaghi (1)

Style	Citing Format
MLA	Taki E, et al.. "Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv." Expert Review of Anti-Infective Therapy, vol. 20, no. 8, 2022, pp. 1135-1147.
APA	Taki E, Soleimani F, Asadi A, Ghahramanpour H, Namvar A, Heidary M (2022). Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv. Expert Review of Anti-Infective Therapy, 20(8), 1135-1147.
Chicago	Taki E, Soleimani F, Asadi A, Ghahramanpour H, Namvar A, Heidary M. "Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv." Expert Review of Anti-Infective Therapy 20, no. 8 (2022): 1135-1147.
Harvard	Taki E et al. (2022) 'Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv', Expert Review of Anti-Infective Therapy, 20(8), pp. 1135-1147.
Vancouver	Taki E, Soleimani F, Asadi A, Ghahramanpour H, Namvar A, Heidary M. Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv. Expert Review of Anti-Infective Therapy. 2022;20(8):1135-1147.
BibTex	@article{ author = {Taki E and Soleimani F and Asadi A and Ghahramanpour H and Namvar A and Heidary M}, title = {Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv}, journal = {Expert Review of Anti-Infective Therapy}, volume = {20}, number = {8}, pages = {1135-1147}, year = {2022} }
RIS	TY - JOUR AU - Taki E AU - Soleimani F AU - Asadi A AU - Ghahramanpour H AU - Namvar A AU - Heidary M TI - Cabotegravir/Rilpivirine: The Last Fda-Approved Drug to Treat Hiv JO - Expert Review of Anti-Infective Therapy VL - 20 IS - 8 SP - 1135 EP - 1147 PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract